Research programme: vasopressin 1b antagonists - Merck/Sanofi Aventis

Drug Profile

Research programme: vasopressin 1b antagonists - Merck/Sanofi Aventis

Alternative Names: ORG 52186; SCH 740935; V3 antagonist - Organon

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Organon
  • Developer Merck & Co; Sanofi
  • Class
  • Mechanism of Action Vasopressin 1b receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Major depressive disorder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
  • 13 Nov 2010 Preclinical trials in Anxiety disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top